EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Treatment targets in IBD: is it time for new strategies?

Fabrizio Fanizzi, Ferdinando D'Amico, Laurent Peyrin-Biroulet, Silvio Danese, Axel Dignass

Best Practice & Research Clinical Gastroenterology · 2025-08 · 77 · 101990

DOI: 10.1016/j.bpg.2025.101990 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Best Practice & Research Clinical Gastroenterology, 2025-08. Verfasst von Fabrizio Fanizzi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Biological Products, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 83 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel diseases' traditional management focused primarily on symptom control, often failing to prevent long-term complications such as disease progression, disabilities, hospitalizations and surgeries. The introduction of biologics and small molecules has revolutionized IBD management, enhancing inflammation control. A pivotal advance in this field is represented by the Treat-to-Target approach, which prioritizes the achievement of specific goals like endoscopic remission and biomarker normalization, thus moving beyond symptomatic relief. The STRIDE recommendations have been pivotal in shaping treatment goals, with STRIDE-II advancing this approach by adding timelines to established targets and suggesting histologic remission for UC and transmural healing for CD as supplementary objectives. Future strategies are expected to incorporate these outcomes, aiming for more comprehensive disease control. This review evaluates whether new therapeutic targets are required to address the unmet needs in IBD management and to further improve longterm patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeCrohn DiseaseBiological ProductsInflammatory Bowel DiseasesGastrointestinal AgentsHumansRemission InductionBiomarkersTreatment Outcome

Stichwörter der Autor:innen

Comprehensive remissionCrohn's diseaseHistologic remissionInflammatory bowel diseaseTransmural healingTreat-to-target strategyUlcerative colitis

Substanzen

BiomarkersBiological ProductsGastrointestinal Agents

Autor:innen und Institutionen

  • Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Gastroenterology, INFINY Institute, INSERM NGERE, CHRU Nancy, F-54500, Vandœuvre-lès-Nancy, France.
  • Department of Medicine I, Agaplesion Markus Hospital, Goethe University, Frankfurt/ Main, Germany. Electronic address: axel.dignass@agaplesion.de.

Zitieren

APA

Fanizzi, F., D'Amico, F., Peyrin-Biroulet, L., Danese, S., & Dignass, A. (2025). Treatment targets in IBD: is it time for new strategies?. Best Practice & Research Clinical Gastroenterology, 77, 101990. https://doi.org/10.1016/j.bpg.2025.101990

Vancouver

Fanizzi F, D'Amico F, Peyrin-Biroulet L, Danese S, Dignass A. Treatment targets in IBD: is it time for new strategies?. Best Practice & Research Clinical Gastroenterology. 2025;77:101990. doi:10.1016/j.bpg.2025.101990

BibTeX
@article{Fanizzi2025,
  author = {Fanizzi, Fabrizio and D'Amico, Ferdinando and Peyrin-Biroulet, Laurent and Danese, Silvio and Dignass, Axel},
  title = {Treatment targets in IBD: is it time for new strategies?},
  journal = {Best Practice & Research Clinical Gastroenterology},
  year = {2025},
  volume = {77},
  pages = {101990},
  doi = {10.1016/j.bpg.2025.101990}
}
Kostenlos starten →